KEYNOTE-B15 ctDNA analysis:

Back to meeting Original

Back to meeting

Kohji Takemura, MD· @KohjiToncol · X·2026-10-23 20:47· 2 days agoScore70

KEYNOTE-B15

Body

KEYNOTE-B15 ctDNA analysis:

Only 4.8% of patients remained ctDNA-positive after neoadjuvant EV + pembrolizumab and radical surgery.

ctDNA-guided treatment strategies may become increasingly important in the EV + pembrolizumab era.

#ESMO26

213 views · 4 likes · 0 reposts · 0 replies

Conference abstracts

4734Omatched by Proffered paper 1: Genitourinary tumour, renal and urothelial

ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin

https://esmocongress.esmo.org

NCT04700124NCT04700124matched by - **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

- **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

https://esmocongress.esmo.org

Source: Kohji Takemura, MD · x.com